Publications
- Zimmermann S., Aghai‐Trommelschlaeger F., Kraus S., Grigoleit G.U., Gesierich A., Schilling B.,Kalogirou C., Goebeler M.E., Kurlbaum M., Klinker H., Isberner N., Scherf‐Clavel O. Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib. J Pharm Biomed Anal (2023) 228:115311. doi: 10.1016/j.jpba.2023.115311
- Isberner N., Gesierich A., Balakirouchenane D., Schilling B., Aghai‐Trommeschlaeger F., Zimmermann S., Kurlbaum M., Puszkiel A., Blanchet B., Klinker H., Scherf‐Clavel O. Monitoring of Dabrafenib and Trametinib in Serum and Self‐Sampled Capillary Blood in Patients with BRAFV600‐Mutant Melanoma. Cancers (2022) 14(19):4566. doi: 10.3390/cancers14194566
- Isberner, N., Kraus, S., Grigoleit, G.U., Aghai, F., Kurlbaum, M., Zimmermann, S., Klinker, H., Scherf‐Clavel, O. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice – a prospective single‐center trial Cancer Chemotherapy and Pharmacology (2021), 88(6): 973‐983. doi: 10.1007/s00280‐021‐04351‐w
- Gerner, B., Scherf‐Clavel, O. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment Pharmaceutics (2021), 13:778. doi: 10.3390/pharmaceutics13060778
- Gerner, B.; Aghai-Trommeschlaeger, F.; Kraus, S.; Grigoleit, G.U.; Zimmermann, S.; Kurlbaum, M.; Klinker, H.; Isberner, N.; Scherf-Clavel, O. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics (2022), 14:2556. doi: 10.3390/pharmaceutics14122556